Kairos Pharma, Ltd. Announces Participation in the D. Boral Capital Inaugural Global Conference
Kairos Pharma (NYSE American: KAPA) has announced its participation in the upcoming D. Boral Capital Inaugural Global Conference on May 14, 2025, at The Plaza Hotel in New York City. The company's CEO and Chairman, John Yu, MD, will be available for one-on-one meetings with interested parties from 9:00 A.M. to 3:00 P.M. (ET). Interested participants can register for meetings by contacting John Perez at jperez@dboralcapital.com.
Kairos Pharma (NYSE American: KAPA) ha annunciato la sua partecipazione al prossimo D. Boral Capital Inaugural Global Conference, che si terrà il 14 maggio 2025 presso l'Hotel Plaza di New York City. Il CEO e Presidente dell'azienda, John Yu, MD, sarà disponibile per incontri individuali con gli interessati dalle 9:00 alle 15:00 (ET). Chi desidera partecipare può prenotare un incontro contattando John Perez all'indirizzo jperez@dboralcapital.com.
Kairos Pharma (NYSE American: KAPA) ha anunciado su participación en la próxima D. Boral Capital Inaugural Global Conference que se celebrará el 14 de mayo de 2025 en The Plaza Hotel de la ciudad de Nueva York. El CEO y presidente de la compañía, John Yu, MD, estará disponible para reuniones individuales con interesados de 9:00 a.m. a 3:00 p.m. (ET). Los participantes interesados pueden registrarse para las reuniones contactando a John Perez en jperez@dboralcapital.com.
Kairos Pharma (NYSE American: KAPA)는 2025년 5월 14일 뉴욕시 플라자 호텔에서 열리는 D. Boral Capital Inaugural Global Conference에 참가한다고 발표했습니다. 회사의 CEO 겸 회장인 John Yu, MD는 오전 9시부터 오후 3시(동부 시간)까지 관심 있는 분들과 일대일 미팅을 진행할 예정입니다. 미팅에 참여를 원하시는 분은 jperez@dboralcapital.com의 John Perez에게 연락하여 등록할 수 있습니다.
Kairos Pharma (NYSE American : KAPA) a annoncé sa participation à la prochaine D. Boral Capital Inaugural Global Conference qui se tiendra le 14 mai 2025 au Plaza Hotel de New York. Le PDG et président de la société, John Yu, MD, sera disponible pour des réunions individuelles avec les personnes intéressées de 9h00 à 15h00 (heure de l'Est). Les participants intéressés peuvent s'inscrire aux réunions en contactant John Perez à l'adresse jperez@dboralcapital.com.
Kairos Pharma (NYSE American: KAPA) hat seine Teilnahme an der bevorstehenden D. Boral Capital Inaugural Global Conference am 14. Mai 2025 im Plaza Hotel in New York City angekündigt. Der CEO und Vorsitzende des Unternehmens, John Yu, MD, steht von 9:00 bis 15:00 Uhr (ET) für Einzelgespräche mit Interessenten zur Verfügung. Interessierte Teilnehmer können sich für Meetings anmelden, indem sie John Perez unter jperez@dboralcapital.com kontaktieren.
- None.
- None.
Los Angeles, California--(Newsfile Corp. - May 6, 2025) - Kairos Pharma, Ltd. (NYSE American: KAPA) today announced its participation in the D. Boral Capital Inaugural Global Conference, taking place May 14, 2025, at The Plaza Hotel in New York City.
John Yu, MD, CEO and Chairman, will be hosting one-on-one meetings on May 14th from 9:00 A.M. to 3:00 P.M. (ET).
To register for one-on-one meetings with management at The Plaza Hotel in New York City, interested parties should contact John Perez at jperez@dboralcapital.com.
About Kairos Pharma, Ltd.
Based in Los Angeles, California, Kairos Pharma Ltd. (NYSE American: KAPA) aims to work at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. Our lead candidate, ENV105, is an antibody that targets CD105 – a protein identified as a key driver of resistance to various cancer treatments. Elevation of CD105 in response to standard therapy results in resistance and disease relapse. ENV105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for lung cancer aimed at addressing significant unmet medical needs. For more information, visit kairospharma.com.
About D. Boral Capital
D. Boral Capital LLC is an investment bank headquartered in New York which provides advisory and financing solutions to middle market and emerging growth companies. The Company has a proven track record of offering strategic guidance to clients across the globe in any sector, with access to capital from the USA, Asia, Europe, Middle East, and Latin America.
D. Boral Capital is a leader on Wall Street, having aggregated over
For further information:
Kairos Pharma, Ltd.
Louie Toma
Investor Relations
774-291-6000
investors@kairospharma.com
www.kairospharma.com
Source: Kairos Pharma, Ltd.
FAQ
When is Kairos Pharma (KAPA) participating in the D. Boral Capital Conference?
Who will represent Kairos Pharma (KAPA) at the D. Boral Capital Conference?
What is the schedule for one-on-one meetings with Kairos Pharma (KAPA) management?
How can investors register for meetings with Kairos Pharma (KAPA) management?
